Mutant TNF-α, mTNF-K90R, is a novel candidate adjuvant for a mucosal vaccine against HIV

Pharmazie

Volumn 65, Issue 4, 2010, Pages 254-256

  Tsunoda, S ^a   Kayamuro, H ^b   Abe, Y ^b   Yoshioka, Y ^b   Katayama, K ^b   Yoshida, T ^b   Yamashita, K ^b   Yoshikawa, T ^b   Kawai, Y ^b   Mayumi, T ^b   Hiroi, T ^b   Itoh, N ^b   Nagano, K ^b   Kamada, H ^b   Tsutsumi, Y ^b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MUTANT TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ENVELOPE PROTEIN GP120; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; OVALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950621498     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9234     Document Type: Article

References (18)

1. Ada G (2001) Vaccines and vaccination. N Engl J Med 345: 1042-1053.
2. Belyakov IM, Berzofsky JA (2004) Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247-253.
3. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA (1998) Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A 95: 1709-1714.
4. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM (2004) Progress on newvaccine strategies against chronic viral infections. J Clin Invest 114: 450-462.
5. Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF (2007) Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVACHIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 46: 222-230.
6. Eriksson K, Holmgren J (2002) Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14: 666-672.
7. Forthal DN, Gilbert PB, Landucci G, Phan T (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178: 6596-6603.
8. Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y, Kamada H, Tsunoda SI, Tsutsumi Y (2009a) TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem Biophys Res Commun 384: 296-300.
9. Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y, Kamada H, Nagano K, Tsunoda SI, Tsutsumi Y (2009b) The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials in press.
10. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
11. Kunisawa J, Gohda M, Kiyono H (2007) [Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine]. Yakugaku Zasshi 127: 319-326.
12. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, ClericiM(1997) HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3: 1250-1257.
13. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
14. Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y (2004) Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 10: 8293-8300.
15. Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, Taniai M, Nomura T, Kayamuro H, Nabeshi H, Sugita T, Imai S, Nagano K, Yoshikawa T, Fujita T, Nakagawa S, Yamamoto A, Ohta T, Hayakawa T, Mayumi T, Vandenabeele P, Aggarwal BB, Nakamura T, Yamagata Y, Tsunoda SI, Kamada H, Tsutsumi Y (2007) Creation and X-ray structure analysis of the tumor necrosis factor receptor- 1 selective mutant of a TNF alpha antagonist. J Biol Chem 283: 998-1007.
16. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346.
17. Watkins DI, Burton DR, Kallas EG, Moore JP, KoffWC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14: 617-621.
18. Yuki Y, Nochi T, Kiyono H (2007) Progress towards an AIDS mucosal vaccine: an overview. Tuberculosis 87: S35-44.